Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
FBIO 
Fortress Biotech Inc (FBIO)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
07/02/2025: FBIO (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
2 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $10
1 Year Target Price $10
| 1 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -75.25% | Avg. Invested days 16 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 07/02/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 53.82M USD | Price to earnings Ratio - | 1Y Target Price 10 |
Price to earnings Ratio - | 1Y Target Price 10 | ||
Volume (30-day avg) 2 | Beta 1.77 | 52 Weeks Range 1.33 - 2.89 | Updated Date 07/2/2025 |
52 Weeks Range 1.33 - 2.89 | Updated Date 07/2/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.13 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -71.24% | Operating Margin (TTM) -169.85% |
Management Effectiveness
Return on Assets (TTM) -32.37% | Return on Equity (TTM) -746.25% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 36717254 | Price to Sales(TTM) 0.93 |
Enterprise Value 36717254 | Price to Sales(TTM) 0.93 | ||
Enterprise Value to Revenue 0.64 | Enterprise Value to EBITDA -0.29 | Shares Outstanding 29569900 | Shares Floating 21991150 |
Shares Outstanding 29569900 | Shares Floating 21991150 | ||
Percent Insiders 21.11 | Percent Institutions 16.61 |
Upturn AI SWOT
Fortress Biotech Inc
Company Overview
History and Background
Fortress Biotech Inc. was founded in 2006. It operates as a biopharmaceutical company focused on acquiring, developing, and commercializing pharmaceutical and biotechnology products, particularly in the areas of oncology, dermatology, and rare diseases.
Core Business Areas
- Drug Development and Commercialization: Focused on developing and commercializing pharmaceutical products, including prescription drugs.
- Subsidiary Management: Fortress Biotech manages a portfolio of subsidiary companies, each focused on specific therapeutic areas or technologies. These subsidiaries include Avenue Therapeutics, Cyprium Therapeutics, and Checkpoint Therapeutics.
Leadership and Structure
Lindsay A. Rosenwald, M.D. serves as Chairman, President, and Chief Executive Officer. The company operates with a decentralized structure, with individual subsidiaries managed by their own leadership teams but overseen by Fortress Biotech's corporate management.
Top Products and Market Share
Key Offerings
- Accutane (isotretinoin): A treatment for severe acne. Fortress markets it through its subsidiary, Journey Medical Corporation. While precise market share data for Journey Medical's specific product offerings isn't readily available, the acne treatment market is competitive, with key players including Sun Pharmaceutical and Teva Pharmaceutical Industries.
- Cosibelimab: Checkpoint Therapeutics, a subsidiary of Fortress Biotech, is developing cosibelimab, an anti-PD-L1 antibody for the treatment of various cancers. If approved, it would compete with established PD-1/PD-L1 inhibitors from companies like Merck (Keytruda) and Bristol Myers Squibb (Opdivo).
Market Dynamics
Industry Overview
The biopharmaceutical industry is characterized by high R&D costs, stringent regulatory requirements, and long development timelines. It is a growing market driven by aging populations and increasing healthcare spending.
Positioning
Fortress Biotech positions itself as an incubator and accelerator of promising drug candidates and technologies. Its competitive advantage lies in its ability to acquire and develop undervalued assets, leveraging its network and expertise.
Total Addressable Market (TAM)
The pharmaceutical market is expected to reach trillions of dollars. Fortress Biotech is positioned to capture a share of this TAM through its pipeline of product candidates and commercialized products.
Upturn SWOT Analysis
Strengths
- Diversified portfolio of subsidiaries
- Experienced management team
- Focus on acquiring and developing undervalued assets
- Strategic partnerships
Weaknesses
- Dependence on subsidiaries' success
- High R&D costs
- Reliance on external funding
- History of operating losses
Opportunities
- Acquisition of new assets
- Expansion into new therapeutic areas
- Regulatory approvals for pipeline products
- Strategic alliances
Threats
- Regulatory risks
- Competition from larger pharmaceutical companies
- Patent expirations
- Clinical trial failures
Competitors and Market Share
Key Competitors
- MRK
- BMY
- LLY
- PFE
- SUNPHARMA.BO
Competitive Landscape
Fortress Biotech faces intense competition from larger, more established pharmaceutical companies with greater resources and broader product portfolios. Its success depends on its ability to identify and develop niche products and effectively manage its subsidiary companies.
Major Acquisitions
Avenue Therapeutics
- Year: 2013
- Acquisition Price (USD millions): 17
- Strategic Rationale: To acquire a late-stage company with a lead product candidate, IV Tramadol, for the treatment of acute post-operative pain. It allowed Fortress to expand its portfolio into pain management.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been uneven, driven by acquisitions and product development milestones. Profitability has been a challenge.
Future Projections: Future growth depends on the success of pipeline products, strategic acquisitions, and commercialization efforts.
Recent Initiatives: Recent initiatives include advancing clinical trials for key drug candidates and exploring strategic partnerships.
Summary
Fortress Biotech operates as an incubator for biopharmaceutical companies, facing high R&D costs. Its decentralized structure allows specialized focus but relies on subsidiary success. Growth depends on pipeline progress and strategic acquisitions. Competitors are much larger and pose a significant threat. Its overall performance should be classified as weak.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Filings (SEC)
- Company Website
- Market Research Reports
- Financial News Sources
Disclaimers:
The information provided is for informational purposes only and should not be construed as financial advice. Market share and financial data are estimates and may vary. Investment decisions should be based on thorough research and consultation with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Fortress Biotech Inc
Exchange NASDAQ | Headquaters Bay Harbor Islands, FL, United States | ||
IPO Launch date 2011-11-17 | Executive Chairman, President & CEO Dr. Lindsay Allan Rosenwald M.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 101 | Website https://www.fortressbiotech.com |
Full time employees 101 | Website https://www.fortressbiotech.com | ||
Fortress Biotech, Inc., a biopharmaceutical company, engages in the development and commercialization of biopharmaceutical products. The company markets dermatology products, including Emrosi, a minocycline hydrochloride extended-release capsule for the treatment of rosacea; Qbrexza a medicated cloth towelette for primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug for severe recalcitrant nodular acne; Amzeeq, a topical formulation of minocycline for inflammatory lesions of non-nodular moderate to severe acne vulgaris; Zilxi for inflammatory lesions of rosacea; Exelderm, an antifungal cream and solution for topical use; Targadox, an oral doxycycline drug for therapy for severe acne; and Luxamend, a water-based emulsion to provide a moist healing environment for superficial wounds, minor cuts or scrapes, dermal ulcers, donor sites, sunburns, and radiation dermatitis. It also develops intravenous Tramadol for the treatment of post-operative acute pain; CUTX-101, an injection for Menkes disease; UNLOXCYT for metastatic cutaneous squamous cell carcinoma; Olafertinib for EGFR mutation-positive NSCLC; CAEL-101, a monoclonal antibody for amyloid light chain amyloidosis; and Triplex, a cytomegalovirus vaccine. In addition, the company's early-stage product candidates include Dotinurad for gout; MB-101 for glioblastoma; MB-108 for recurrent GBM; MB-109 for refractory glioblastoma and anaplastic astrocytoma; MB-106 for B-cell non-hodgkin lymphoma; AJ201, an androgen receptor degradation enhancer; and BAER-101, a positive allosteric modulator. Further, its preclinical product candidates comprise AAV-ATP7A and AVTS-001 gene therapies; CK-103 BET inhibitor; CEVA-D and CEVA-102; CK-302, an anti-GITR; CK-303, an anti-CAIX; and oligonucleotide platform. The company was formerly known as Coronado Biosciences, Inc. and changed its name to Fortress Biotech, Inc. in April 2015. Fortress Biotech, Inc. was incorporated in 2006 and is based in Bay Harbor Islands, Florida.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.